Viral replication machinery in Rb-defective tumor cells (Delta-24) (Delta-24)

The viral replication machinery in Rb-defective tumor cells refers to a specialized therapeutic target system where oncolytic viruses are engineered to exploit the loss of the Retinoblastoma (Rb) tumor suppressor pathway. In a healthy physiological state, the Rb protein acts as a gatekeeper of the cell cycle by sequestering E2F transcription factors, thereby inhibiting the transition to the S-phase and preventing the replication of viruses that rely on host machinery (Fueyo et al., 2000, Oncogene). Oncolytic adenoviruses like DNX-2401 (Tasadenoturev) contain a specific 24-base-pair deletion in the E1A gene (Delta-24), which renders the viral E1A protein unable to bind and inactivate Rb. Consequently, these viruses cannot replicate in normal cells where Rb is functional. However, in many tumors, the Rb pathway is already disrupted, leading to an abundance of free E2F that the engineered virus can utilize to initiate its replication cycle (Lang et al., 2018, J. Clin. Oncol.). This selective replication results in the destruction of the tumor cell through lysis and the induction of a secondary anti-tumor immune response as viral and tumor antigens are released into the microenvironment (Jiang et al., 2007, Clin. Cancer Res.). This approach is primarily investigated for the treatment of high-grade gliomas and other Rb-deficient malignancies (Alonso et al., 2008, Mol. Ther.).

Other names

Rb-selective oncolytic adenovirusDelta-24 adenovirusE1A-modified viral replication systemRb/E2F-targeted oncolytic machineryDNX-2401 replication complex

Selective viral replication and oncolysis in Rb-deficient cells via E1A-mediated exploitation of free E2F transcription factors (Fueyo et al., 2000, Oncogene).